Medivir AB (STO:MVIR-B) announced today that the Russian Ministry of Health has approved Sovriad(R) (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
Help employers find you! Check out all the jobs and post your resume.
